Deadly Explosion at E-Cigarette Factory in Detroit, Michigan

News by 2FIRSTS.ai
Mar.06.2024
Deadly Explosion at E-Cigarette Factory in Detroit, Michigan
A deadly explosion at an e-cigarette factory in Detroit, Michigan, leaves one dead and several injured.

According to a report by the American media on March 6, a large-scale fire broke out at an e-cigarette manufacturing factory in Detroit, Michigan, in the Midwest, and metal fragments flying out of the explosion directly caused one death.

 

A fire broke out at an e-cigarette manufacturing factory on the outskirts of Detroit, Michigan. The explosion occurred around 8:50 PM local time on March 4th, prompting authorities to urge residents in the area to stay indoors. According to local media reports, there were hundreds of explosions at the scene, and a 19-year-old man was killed when he was hit by a metal container that was thrown by one of the explosions roughly 400 meters away from the site. The man was reportedly "just watching" the fire when he was hit.

 

According to the investigation, a large amount of butane gas used for gas tanks is stored inside the factory, which may have sparked the fire. The fire department is urging residents in the surrounding area to evacuate, as there is a risk of being hit by flying debris within a radius of approximately 1.6 kilometers from the building.

 

Investigators will continue to look into the legality of the items stored within the building.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

PMI says it submitted evidence to FDA panel backing ZYN bid for modified-risk status
PMI says it submitted evidence to FDA panel backing ZYN bid for modified-risk status
Philip Morris International said it presented scientific evidence to the U.S. Food and Drug Administration’s Tobacco Products Scientific Advisory Committee to support its ZYN nicotine pouches seeking a modified risk tobacco product designation, which would allow the company to communicate to adult smokers that switching completely to ZYN could reduce the risk of multiple smoking-related diseases.
Jan.26 by 2FIRSTS.ai
U.S. Washington State to Bring Synthetic Nicotine Under the Tobacco Tax System, Applying a Unified Tax Starting January 2026
U.S. Washington State to Bring Synthetic Nicotine Under the Tobacco Tax System, Applying a Unified Tax Starting January 2026
Washington State will subject all nicotine-containing products to the Tobacco Products Tax starting January 1, 2026, taxing them at 95% of the selling price. The change covers both tobacco-derived and synthetic nicotine products and requires businesses to report their inventory when the new tax system takes effect.
Dec.29 by 2FIRSTS.ai
Indiana SB 185 Advances: Foreign-Made Vapes Would Be Barred, With Focus on China
Indiana SB 185 Advances: Foreign-Made Vapes Would Be Barred, With Focus on China
Indiana State Sen. Ron Alting is backing Senate Bill 185, which would ban vape shops in Indiana from selling any foreign-made vaping products and restrict retail shelves to U.S.-made items. Alting has framed the proposal as a consumer-safety measure and has singled out China, citing industry reporting that China produces more than 90% of the world’s vape hardware.
Jan.27 by 2FIRSTS.ai
BAT FY2025 Results Review Series by 2Firsts
BAT FY2025 Results Review Series by 2Firsts
Feb.12
France drops a vaping clause from the 2026 finance bill after use of Article 49.3
France drops a vaping clause from the 2026 finance bill after use of Article 49.3
A provision in France’s 2026 finance bill intended to regulate vaping products was abandoned after Sébastien Lecornu used Article 49.3 on January 20 to commit the government’s responsibility on the “revenue” section of the state budget.
Jan.21 by 2FIRSTS.ai
FDA Details Carcinogenicity Tiering and ELCR Framework as Small Manufacturers Press for Predictability
FDA Details Carcinogenicity Tiering and ELCR Framework as Small Manufacturers Press for Predictability
During the “Toxicological Profile” session at FDA’s Feb 10 PMTA roundtable, officials outlined the carcinogenicity tiering system and Excess Lifetime Cancer Risk (ELCR) framework used in ENDS reviews under the APPH standard. Small manufacturers questioned database transparency, exposure assumptions, and the existence of clear compliance benchmarks. FDA reiterated toxicological risk is assessed case by case within a broader population-level determination.
Feb.11